Investors who have purchased common stock of QuidelOrtho Corporation (NASDAQ: QDEL) between February 18, 2022, and April 1, 2024, are reminded of the upcoming lead plaintiff deadline on June 11, 2024. The Rosen Law Firm, a recognized global investor rights law firm, urges investors to take action if they wish to be eligible for potential compensation.
During the mentioned Class Period, it is alleged that QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers. This led to excess inventories of COVID-19 tests throughout the supply chain. As a result, QuidelOrtho’s distributors and pharmacy chain customers were expected to significantly reduce their COVID-19 test orders. Additionally, undisclosed problems raised concerns about the timely commercial launch of the Savanna RVP4 Test, QuidelOrtho’s flagship product.
Investors who suffered damages as a result of these alleged misleading statements and omissions may be entitled to compensation. The Rosen Law Firm advises investors to consider joining the class action by contacting Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] Alternatively, investors can fill out the form at https://rosenlegal.com/submit-form/?case_id=22828 to get information on the class action.
When selecting legal representation, it is crucial for investors to choose qualified counsel with a proven track record of success. The Rosen Law Firm specializes in securities class actions and shareholder derivative litigation and has a history of achieving substantial recoveries for investors. Qualified counsel ensures that investors have adequate representation in directing the litigation and safeguarding their rights.
Please note that no class has been certified yet, and investors are advised to retain counsel until a class certification occurs. However, investors also have the option to remain an absent class member and take no action at this point. Their ability to share in any potential future recovery is not dependent upon serving as the lead plaintiff.
Stay updated on the latest developments by following The Rosen Law Firm on LinkedIn, Twitter, and Facebook. Previous success does not guarantee similar outcomes in future litigation. For further information and contact details, please visit www.rosenlegal.com.
Disclaimer: This article is for informational purposes only and does not constitute legal advice.
Important Deadline for QuidelOrtho Corporation Investors
In addition to the information provided in the article, it is important to consider some current market trends and forecasts related to QuidelOrtho Corporation.
1. Current Market Trends: The COVID-19 pandemic has significantly increased the global demand for diagnostic testing, including COVID-19 tests. As a result, many companies in the healthcare sector, including QuidelOrtho Corporation, experienced a surge in sales for their diagnostic products during the initial stages of the pandemic.
2. Forecasts: With the ongoing vaccination efforts and the gradual reopening of economies, the demand for COVID-19 tests is expected to decline in the coming months. This anticipated decrease in demand may have an impact on the financial performance of companies like QuidelOrtho Corporation, especially if they have excess inventory of COVID-19 tests.
3. Key Challenges and Controversies: QuidelOrtho Corporation is facing allegations that it sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers. This has resulted in excess inventories and concerns about the timely commercial launch of the Savanna RVP4 Test. These challenges may lead to financial repercussions for the company and potential legal actions from investors seeking compensation.
Advantages of Taking Action:
– Eligibility for potential compensation: By joining the class action, investors may be eligible for compensation if they have suffered damages as a result of alleged misleading statements and omissions by QuidelOrtho Corporation.
– Legal representation: The Rosen Law Firm specializes in securities class actions and has a proven track record of achieving substantial recoveries for investors. Having qualified counsel can safeguard investors’ rights and ensure adequate representation in the litigation process.
Disadvantages of Taking No Action:
– Limited potential for recovery: If investors choose to remain absent class members and take no action, their ability to share in any potential future recovery may be compromised.
– Lack of active involvement: By not actively participating in the class action, investors may have limited opportunities to provide input or influence the litigation process.
For more information and to stay updated on the latest developments, investors can follow The Rosen Law Firm on LinkedIn link name, Twitter link name, and Facebook link name. However, it’s essential to note that previous success in litigation does not guarantee similar outcomes in future cases.
For further information and contact details, visit the official website of The Rosen Law Firm at www.rosenlegal.com link name.
Disclaimer: The information provided in this article is for informational purposes only and should not be considered as legal advice. Investors are encouraged to seek qualified legal counsel for advice on their specific situation and potential participation in the class action.